Skip to content

Food and Drug Recall.org

The Latest Food & Drug Recall and Safety News

FDA approves Surfaxin to prevent breathing disorder in premature infants

March 6, 2012Drug Recalls & Safety Notices, Drug Safety Information Podcasts, Food & Drug Recalls, Food Safety Newsadmin

The U.S. Food and Drug Administration today approved Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.

Post navigation

← Price Chopper Supermarkets Recalls Streusel Topped Fruit Pies FDA Commissioner Margaret A. Hamburg’s Statement on the Surgeon General’s Report →
Proudly powered by WordPress